17 March 2020
Visiongain has launched a new pharma report Global Clinical Trial Management System Market Forecast 2020-2030.
The Global Market for Clinical Trial Management System is favoured by technological advancements and the rise of e-clinical platforms within clinical research organisations will continue to drive and take on more clinical trial projects. Continued market disruption by multiple industry forces such as advances in medicine, technology, and cost pressures will also allow now point solution vendors to distinguish themselves and their services over platform vendors. This dynamic will support ongoing diversity in the CTMS technology ecosystem even as the benefits of the CTMS platform continue to grow.
The lead analyst of the report commented "The clinical trials management system market is expected to witness a robust growth during the years of forecast owing to the rise in the number of clinical trials, rising investments in CTMS and advancements in technology. Clinical trial technology vendors have taken the pace of consolidating and incorporating technologies and resources into cloud-based e-clinical systems that support many clinical trial processes. Advanced technologies such as AI, better visualisations and analytics are enabling clients to unlock significant efficiencies in R&D. Having said this, many CROs are entering the CTMS space and increasingly developing their own solutions, this has led to talent poaching and increased competition on the market."
Leading companies featured in the report include Parexel Informatics Inc, Oracle, Medpace Holdings. Mednet Solutions, ERT Clinical, DataTRAK Internationals, Inc and many others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical companies. New market dynamics including an evolving product line, more stringent regulations, geographically connected supply chains, rising risk, and extreme cost pressure have raised stakes significantly.
28 September 2020
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.